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Background: Seasonal variations have been reported for immune markers. However, the
relative contributions of sunlight and vitamin D variability on such seasonal changes
are unknown.
Objective: This double-blind, randomized, placebo-controlled trial tested whether daily
400 IU vitamin D3 supplementation affected short-term (12 weeks) and long-term (43
weeks) natural regulatory T cell (nTreg) populations in healthy participants.
Design: 62 subjects were randomized equally to vitamin D versus placebo in March and
assessed at baseline, April (4w), June (12w), September (25w) and January (43w).
Circulating nTregs, ex vivo proliferation, IL-10 and IFN-g productions were measured.
Vitamin D metabolites and sunlight exposure were also assessed.
Results: Mean serum 25-hydroxyvitamin D (25(OH)D) increased from 35.8(SD 3.0) to
65.3(2.6) nmol/L in April and remained above 75 nmol/L with vitamin D supplementation,
whereas it increased from 36.4(3.2) to 49.8(3.5) nmol/L in June to fall back to 39.6(3.5)
nmol/L in January with placebo. Immune markers varied similarly between groups
according to the season, but independently of 25(OH)D. For nTregs, the mean (%
CD3+CD4+CD127lo cells (SEM)) nadir observed in March (2.9(0.1)%) peaked in
September at 4.0(0.2)%. Mean T cell proliferation peaked in June (33156(1813) CPM)
returning to the nadir in January (17965(978) CPM), while IL-10 peaked in June and
reached its nadir in September (median (IQR) of 262(283) to (121(194) pg/ml,
respectively). Vitamin D attenuated the seasonal increase in IFN-g by ~28% with mean
ng/ml (SEM) for placebo vs vitamin D, respectively, for April 12.5(1.4) vs 10.0(1.2)
(p=0.02); June 13.9(1.3) vs 10.2(1.7) (p=0.02) and January 7.4(1.1) vs 6.0(1.1) (p=0.04).org June 2021 | Volume 12 | Article 6230871
Abbreviations: FoxP3, forkhead box P
interleukin 10; PBMCs, peripheral blood
hormone; Treg, regulatory T cell; 25(OH)D
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Frontiers in Immunology | www.frontiersin.Conclusions: Daily low dose Vitamin D intake did not affect the nTregs population. There
were seasonal variation in nTregs, proliferative response and cytokines, suggesting that
environmental changes influence immune response, but the mechanism seems
independent of vitamin D status. Vitamin D attenuated the seasonal change in T cell-
produced IFN-g, suggesting a decrease in effector response which could be associated
with inflammation.
Clinical Trial Registration: https://www.isrctn.com, identifier (ISRCTN 73114576).Keywords: vitamin D, randomized control trial, T regulatory cells, interferon-gamma, seasonality, healthy subjects,
immune markersINTRODUCTION
Vitamin D deficiency has re-emerged as a global concern (1, 2).
Due to low UVB availability, populations at high latitudes are
predisposed to lower vitamin D levels (3). For bone health, UK
government currently advises daily vitamin D intake of 10 mg
(400 IU) throughout the year for the general population from 4
years old (SACN, 2016). It is unknown whether these are optimal
for functions other than calcium homeostasis (4). Vitamin D
deficiency may affect immune system functionality, leading to
increased risk of severe infections, metabolic syndrome and
autoimmunity (5, 6).
Research on vitamin D’s immunomodulatory effects
primarily have focused on the in vitro effects of the active
metabolite, 1,25(OH)2D, or its analogues (7, 8). Key targets for
vitamin D include forkhead box P3 (FoxP3) transcription factor,
the master regulator of regulatory T cells (Tregs) and interferon-
gamma (IFN-g) (9, 10). Tregs play a crucial role in immune
homeostasis by regulating the magnitude of other immune cell
responses (11) and maintaining self-tolerance (12, 13).
Few human intervention studies on the effects of vitamin D3
on Tregs and other immune markers have been conducted (14).
Furthermore, these studies have either administered very high
doses in healthy participants (15, 16) or used supplementation as
a therapeutic agent in pre-existing disease (17, 18). Healthy
participants supplemented with cholecalciferol (~5000 IU/day)
over 12 weeks during wintertime showed a significant increase in
Tregs (16), but it was not confirmed whether this was sustained
throughout the summer or attained at lower doses. Treg
population, defined as CD25hiCD127−CD4+ T cells, did not
change their numbers, although higher FoxP3 expression was
observed in the summer when solar UVB and vitamin D levels
are at their peak (19). Seasonal cycles have been described in
other immune markers (20) and may help explain the seasonal
incidence of illnesses e.g. wintertime influenza (21), and
mortality in a natural population (22), as well as the seasonal
incidences of some autoimmune conditions (e.g. inflammatory
bowel disease) (23), but the contribution of vitamin D
is uncertain.3; IFN-g, interferon-gamma; IL-10,
mononuclear cells; PTH, parathyroid
, 25-hydroxy vitamin D; 1,25(OH)2D,
4,25 dihydroxy vitamin D.
org 2The primary aim of this study was to investigate the effect of
oral vitamin D3 at UK population-recommended doses on nTreg
populations. We investigated whether treating healthy adults
with 400 IU vitamin D daily would increase nTregs within 12
weeks and whether any increase would be maintained for 10
months, independently of seasonal changes. We also assessed T
cell proliferation and PBMC’s-derived IL-10 and IFN-g
production in response to control stimuli.METHODS
Study Population
Healthy adults (>18 years) from the Aberdeen area in NE
Scotland (57°N) were recruited to this double-blind,
randomized, placebo-controlled trial using local advertising
and screened by telephone or personal interview. People
taking ≤ 200 IU/day vitamin D at screening were eligible if
they discontinued the supplements at least 1 month
before baseline.
Exclusion criteria included being pregnant or lactating, receiving
immunosuppressive or regular use of anti-inflammatory
medication, or continuing to take supplements containing >100
IU vitamin D. Anyone with an immune-mediated disorder,
rheumatoid arthritis, multiple sclerosis, asthma, hay fever, lupus
or eczema; kidney disease; cancer or other serious immune
compromising conditions, or who planned holidays abroad (> 1
month to sunny destinations), or had used sunbeds in the last 3
months were also excluded.
Full written informed consent was obtained from all
participants and ethical approval for this study was granted by
the College of Life Sciences and Medicine Ethics Review Board
(CERB), University of Aberdeen. The procedures followed were
under the Helsinki Declaration of 1975 as revised in 1983. The
study was registered at the ISRCTN registry for clinical research
trials (ISRCTN: 73114576).
Intervention
Participants were randomly assigned to receive one capsule of
400 IU vitamin D3 (UK RNI dose, 10mg cholecalciferol; n = 31
VitD3 group) or placebo (n = 31 placebo group) daily for 43
weeks. Permuted block randomization (size of 8) was conducted
using a web-based system managed by the Health ServiceJune 2021 | Volume 12 | Article 623087
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provided by Pure Encapsulations (Sudbury, MA) and matching
placebo by Cultech, UK. Capsules were opaque, contained the
same excipient (blend of fructooligosaccharides, microcrystalline
cellulose, silica, and magnesium stearate) and were similar in size
and color. Compliance was assessed by counting leftover
capsules at the end of the intervention period. Participants and
investigators were blinded to the intervention’s treatments.
Participants attended the Health Sciences Building at the
University of Aberdeen for assessment at 5-time points:
starting in March 2015 with baseline (March, spring), 4 weeks
(April, spring), 12 weeks (June, summer), 25 weeks (September,
autumn) in 2015 and the last visit at 43 weeks in January 2016
(winter). Baseline assessment included demographic questions,
age , he i gh t , we igh t , sk in co lo r us ing CM-2600d
Spectrophotometer, dietary vitamin D intake and a sunlight
questionnaire to estimate seasonal sunlight behaviors (time
spent outside and body surface exposure for each season).
Venesection and Blood Processing
Subjects provided 45mL fasted blood samples at each visit
collected into the following tubes: Lithium heparin sulfate
tubes (3 x 9mL) and serum activated clot VACUETTE® tubes
(1 x 9mL) (Greiner Bio-One, Austria) for the analysis of immune
markers, Serum Separator Tubes (1 x 5mL, SST™ tube) and
EDTA tubes (1 x 4mL) both from BD Vacutainer® (UK) for
vitamin D metabolites and PTH levels, respectively.
Peripheral Blood Cell Preparation
Peripheral blood mononuclear cells (PBMCs) were isolated from
heparinized venous whole blood by density-gradient
centrifugation (Lymphoprep, Axis-Shield, Oslo, Norway).
PBMCs were resuspended in Alpha modification of Eagle’s
medium (Gibco, Glasgow, UK), supplemented with 5%
autologous serum for the measurement of immune markers.
Tissue Culture
PBMCs were cultured in duplicates of 1mL volumes in 24-well
tissue culture plates at 1.25x106/mL at 37°C in a humidified
atmosphere of 5% CO2/95% air and were stimulated for 3 days
with 2.5x105 beads/mL anti-CD3/anti-CD28-coated beads
(Dynabeads human T-Activator, Invitrogen, Glasgow, UK) or 1%
Concanavalin A (ConA, positive control) or were left unstimulated.
Proliferation Assays
Proliferation was measured as the incorporation of 3H-
thymidine (18.5 kBq, Amersham Biosciences, Amersham, UK)
over the final 6h of a 72-h culture period. Cells were then
harvested onto glass-fiber filter mats (LKB-Wallac Ltd, Turku,
Finland) using a Mach III harvester and the radioactivity was
measured by liquid scintillation (Microbeta+, LKB-Wallac).
Proliferation results are presented as counts per minute
(CPM) ± SEM of triplicate samples.
Cytokine Production
As the cytokines were measured after the PBMC were incubated
with T cell stimuli, the cellular source is likely to beFrontiers in Immunology | www.frontiersin.org 3predominantly T cells. IL-10 and IFN-g concentrations in cell
cu l ture medium were ana lyzed by enzyme- l inked
immunosorbent assay. All antibodies and reagents for this
assay and nTreg quantification were supplied by Becton
Dickinson Pharmingen (San Diego, California) unless
otherwise stated. The antibody pairs for human cytokines were
anti‐IFN‐g (clones NIB42 and 4S.B3 BD) and anti‐IL‐10 (clones
JES3-19F1 and JES3-12G8), used at 2 mg/L and 1 mg/mL,
respectively. Cytokine concentrations were measured in 100µL
duplicate samples of 3-day stimulated PBMC culture
supernatants. Reconstituted (in phosphate buffer saline
containing 5 mg/mL bovine serum albumin) recombinant
human IFN-g (500 mg/mL) and Recombinant Human IL-10
(100 mg/mL) were used for generating standard curves. The
wells were developed with 1/10,000 ExtraAvidin®-alkaline
phosphatase conjugate and phosphatase substrate (Sigma-
Aldrich, USA), and absorbance determined at 405 nm using a
Multiskan™ plate reader (Labsystems, Basingstoke, UK). The
standard curves were modelled by a smoothed cubic spline
function, which was applied to the absorbance readings and
the cytokine concentrations after a quasi-logarithmic
transformation, where: quasiloge = loge [z + √ [z
2 + 1]].
Natural Treg Quantification
Freshly isolated PBMCs were stained using the following
fluorescentally-labelled monoclonal antibodies: anti-CD3-FITC
(clone HIT3a, 20ml/test), anti-CD4-PerCP-CY5.5 (clone RPA-T4,
5ml/test), anti-CD25-APC (clone M-A251, 5ml/test), anti-CD127-
PE-CY7 (clone HIL-7R-M21, 5ml/test). Cells were also fixed and
permeabilized as per manufacturer’s protocol using the human
FoxP3 buffer Set before the intracellular staining of Human FoxP3
by anti-FoxP3-PE (clone 259D/C7, 20ml/test). All data were
acquired using the LSR II (BD Biosciences, San Diego, California)
and analyzed using FlowJo v.9.3.1 (Tree Star, Inc, Ashland, Ore). PE
isotype, CD25 and FoxP3 minus one (FMO) controls were run
during each experiment and compensation beads were used for
each sample, providing single positive controls for voltage
adjustments and compensation calculations. The Treg population
investigated in this study are the thymus-derived Treg or naturally
occurring Tregs (nTregs), identified as the proportion (percentage)
of CD3+CD4+CD127lo cells with a CD25+FoxP3+phenotype
(%nTreg).
Vitamin D Metabolites and
Parathyroid Hormone
Biochemical analysis was performed at the Bioanalytical Facility
(University of East Anglia, Norwich, UK). Serum 25(OH)D3, 25
(OH)D2, 24,25(OH)2D3 and 24,25(OH)2D2 concentrations were
determined simultaneously from a single analysis by liquid
chromatography-tandem mass spectrometer as described
previously (24). Briefly, serum samples extracted using
supported liquid extraction plates (Biotage, Uppsala, Sweden)
to de-lipidate phospholipids, followed by derivatization with 4-
Phenyl-1,2,4-triazole-3,5-dione. 25(OH)D3 and D2 were
calibrated using commercial standards (Chromsystems,
München) traceable to standard reference material SRM972a
from the National Institute of Science and Technology. The assayJune 2021 | Volume 12 | Article 623087
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coefficient of variation (CV) was ≤9%, the lower limit of
quantification (LLoQ) of 0.1 nmol/L. The assay showed <8%
accuracy bias against NIST reference method on the Vitamin D
external quality assessment scheme. 24,25(OH)2D3 and 24,25
(OH)2D2 were calibrated using in-house spiked standards
traceable to NIST SRM972a. The assay was linear between 0.1-
25 nmol/L; inter/intra-assay CV was ≤11%, LLoQ of 0.1 nmol/L
for 24,25(OH)2D3 and 0.8 nmol/L for 24,25(OH)2D2. Total 25
(OH)D and 24(OH)2D were reported as the sum of their
respective (D2+D3) forms.
Serum 1,25(OH)2D was analyzed by chemiluminescent
immunoassay using the DiaSorin LIAISON® XL automated
analyzer (Stillwater, MN, USA). The assay measured total 1,25
(OH)2D between 12-480 pmol/L, the inter/intra-assay CV
were ≤9.2%. On the Vitamin D external quality assessment
scheme, the method showed ≤8.5% bias against method-
specific mean and ≤9.1% bias against all method mean.
Plasma PTH was analyzed on the COBAS platform by
electrochemiluminescence immunoassay (Roche Diagnostics,
Mannheim, Germany). The inter-assay CV was ≤3.8% across
the analytical range of 1.2-5000 pg/mL.
Other Analyses
Sunlight UVB exposure was measured over 7 consecutive days
using UVB polysulfone film badges, one week after the baseline,
weeks 4, 12 and 25 study visits. An extra measurement was taken
at week 16 at the peak of the summer period in July. The
absorbance of the badges pre- and post-solar UVB exposure,
was measured by standard measures and the standard erythema
dose was calculated as 10.7 (DA330) +14.3 (DA330)2−26.4
(DA330)3+89.1 (DA330)4 where DA330 is equal to the
difference in readings (25, 26). A daily sunlight diary
accompanied the badges to collect information such as the
amount of time spent outdoors, and skin exposed for each day
the badges were worn. Holidays taken over the study period were
also recorded. Skin color (as individual topology angle) was
measured at each visit on the skin surface of 4 sites in the
following sequence: left and right cheekbones, and the inner and
outer right forearm, as previously described (27, 28). The
individual topology angle was defined using the following
equation: ITA = (arctangent (L* − 50)/b*) × 180/p (29).
Statistical Analysis
Using data that showed a mean increase in natural log %nTregs
of 1.68 (SD 1.93) (27), it was estimated that 25 subjects would be
required to detect the same difference in Tregs with 85% power
and a significance level of 5% (PS Power version 3.0.43). Based
on previous studies (3, 30), sixty volunteers (30 subjects in each
arm) were recruited to allow for 20% withdrawal. Baseline
characteristics were described for each group using mean and
standard error mean (SEM) for normally distributed continuous
variables and median (IQR) for those skewed, with number and
percentage for categorical variables. A linear mixed model was
used to compare the change in vitamin D metabolites with
supplementation at each visit. A linear mixed model was also
used to compare treatment groups (VitD3 versus placebo) forFrontiers in Immunology | www.frontiersin.org 4their immune marker response (nTregs, T cell proliferation, IL-
10 or IFN-g) over time (visit) adjusted for other confounders
(age, height, weight, dietary vitamin D, sunlight exposure,
a holiday abroad, and skin pigmentation). An a priori decision
was made to conduct a sensitivity analysis including
compliance >85%. Results were analyzed using SPSS version 24.RESULTS
Participants Recruitment and Baseline
Characteristics
Eighty individuals were assessed for eligibility; sixty-two non-
smokers met the inclusion criteria, of whom seven withdrew for
the following reasons: poor health (n=1), time constraints (n=1),
job relocation (n=2), blood sampling (n=1), long sunny holiday
(n=1) and personal reasons (n=1) (Figure 1). From these seven
volunteers, three others were randomized but 2 of these failed to
attend the baseline visit, and the third attended but did not
provide a sample and withdrew from the study. No-one reported
taking supplements containing vitamin D; 9 participants (n 5,
placebo vs n 4, VitD3) reported a winter-time holiday before
study commencement; 2 participants (VitD3 group) reported
using a sunbed (> 3 months ago). Baseline characteristics are
summarized in Table 1. Baseline mean (SEM) serum 25(OH)D
concentrations were similar between placebo (36.4(3.2) nmol/L)
and VitD3 (35.8(3.0) nmol/L) groups. Baseline serum
concentrations for 1,25(OH)2D, its catabolic marker 24,25
(OH)2D and PTH were also similar between the groups. At
baseline, 29% and 32% of subjects in the placebo and VitD3
group, respectively, had 25(OH)D concentrations < 25 nmol/L.
Compliance with the intervention was similar between the
groups and over 85% in both groups.
Sun Exposure and Skin Pigmentation
Median (IQR) of the standard erythema dose in the placebo
group increased from 1.7(3.6) in March, to 3.7(6.7) in April (4w),
4.9(5.8) in June (12w), 3.7(5.0) in July (16w), and decreased to
2.2(2.1) in September. Similarly, weekly UVB exposure in March
was low in the VitD3 group, peaked in the summer before
declining in the autumn. There was no significant difference in
sunlight UVB exposure between the groups (data not shown).
Skin pigmentation was also not statistically different between
groups and varied similarly over time in both groups as darker
skin pigmentation was measured in April, June and September
compared to baseline (p<0.001, at each timepoint). For the
placebo group, the mean (SEM) skin pigmentation in March
decreased over the summer from an ITA of 41.8(1.5), reaching
the nadir (greatest skin darkening) in September (36.5(1.6)),
before returning to baseline the following January (40.7(1.0)).
Skin pigmentation for VitD3 in September was 38.3(2.0), 13%
lower than baseline value in March (43.2(1.7)).
Vitamin D Metabolites and PTH
In the placebo group, mean (SEM) 25(OH)D concentrations
changed seasonally, increasing to 40(3.0) nmol/L in April (4w),
50(3.5)nmol/L in June (12w), 60(4.6) nmol/L in September (25w)June 2021 | Volume 12 | Article 623087
Maboshe et al. Vitamin D3 and Immune Markersand returning to baseline (40(3.5) nmol/L) in January (43w).
Vitamin D treatment resulted in an 82% increase in 25(OH)D to
a mean of 65(3.0) nmol/L in April (4w) with a plateau of around
80-85 nmol/L in June and September before decreasing slightly
to 75(4.0) nmol/L the following January (Figure 2A). Vitamin D
supplementation showed a similar pattern of increased 24,25
(OH)2D concentrations compared to placebo (data not shown).Frontiers in Immunology | www.frontiersin.org 5For both metabolites, mixed models showed significant time-
treatment interactions (P<0.001, at each time point from April
to January).
For 1,25(OH)2D, a change over time was observed but with no
significant difference between treatment and placebo (Figure 2B).
The ratio of 1,25(OH)2D to 24,25(OH)2D varied seasonally
for the placebo group, reaching a trough of 40 in September andFIGURE 1 | Participants’ enrolment and retention: a and b - withdrew from the follow-ups but returned for the final visit; 1 and 2 – Individuals unable to attend more
than 1 study visit.June 2021 | Volume 12 | Article 623087
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had a consistently lower value that plateaued at a ratio of 20
from June until the following January. The time-treatment
interactions were significant at each time point (April
P<0.001, June P=0.001, September P=0.02, January P<0.001)
(Figure 2C). Plasma PTH concentration did not change with
time although treatment resulted in a marginal reduction
overall (p=0.02) (Figure 2D).
nTregs and T Cell Proliferation
The %nTregs and T cell proliferation values were similar
between treatment groups at baseline. There was no significant
association between serum 25(OH)D concentrations (or the
concentrations of 24,25(OH)2D, 1,25(OH)2D, or ratios of
vitamin D metabolites) and baseline %nTregs. Vitamin D
supplementation did not appear to affect nTregs, although
there was a seasonal increase in summer that was very similar
to the placebo (Figure 3A). The %nTregs (placebo group)
increased gradually from a mean (SEM) of 2.9(0.2)% in March
to peak in June and September to 3.8(0.3)% and 4.0(0.4)%,
respectively, then decreasing to 3.4(0.4)% in January. The
seasonal pattern remained significant (P<0.001 for June,
September and January) after adjustment for confounders, with
skin color (P<0.001) and body weight (P=0.015) being
additional predictors.
There was no correlation between 25(OH)D or any other
vitamin Dmetabolite and induced T cell proliferation at baseline;
and vitamin D supplementation did not appear to affect
proliferative responses. T cell proliferation was similar between
groups at every time point, and followed similar changes
according to the season, from a mean of 21851(1398) cpm and
19380(1536) cpm in March and April, respectively, to a
significantly higher response in June of 34463(2359), before
returning to 21880(1794) and 19207(1458) in September and
January, respectively for placebo (Figure 3B). Mixed modelling
showed significant differences from baseline in June (P<0.001)
and January (P<0.001) after adjustment for confounders, with
PTH being an additional predictor (P=0.027).Frontiers in Immunology | www.frontiersin.org 6Stimulated-Cell Cytokine Production
There was a weak positive association between 25(OH)D
(but not other vitamin D metabolites) and secreted IL-10
concentrations from stimulated PBMCs at baseline
(Spearman’s r 0.270, p=0.044). There was no significant effect
from vitamin D supplementation, but seasonal differences were
broadly similar between the treatment groups (Figure 4A). In
the placebo group, median (IQR) IL-10 concentrations for
March, April, June were 228(248), 271(230), 344(304) pg/ml,
respectively, which were higher than those for September and
January (101(207) and 165(161), respectively. The vitamin D3
group showed median (IQR) for IL-10 for March, April, June of
250(433), 248(283), 202(278) in pg/ml compared to 143(148)
and 115(120) in pg/ml in September and January, respectively.
Mixed modelling showed IL-10 concentrations to be significantly
greater in June compared to baseline (P<0.001), after adjustment
for confounders and that dietary vitamin D was an additional
predictor (P=0.037, Table 2).
Similar seasonal variation was observed for IFN-g and
vitamin D appeared to attenuate the increase seen in April and
June in the placebo group. The corresponding medians (IQR) in
ng/ml for the placebo group were 10.5(12.2), 13.7(11.8) in April
and June compared to 7.8(11.5), 9.7(11.9) for the VitD3 group,
which equates to a reduction of 26% and 29% respectively
(Figure 4B). Mixed modelling showed a significant time-
treatment interaction for IFN-g (Table 2), which remained
significant after testing for other variables. This indicates the
effect of treatment differs with time and does not remain
constant. Gender and body weight were found to be additional
predictors of IFN-g concentration but not age, 25(OH)D,
PTH, holidays abroad, dietary vitamin D, nor skin color.
Sensitivity analysis, including compliance >85%, did not
affect the results of the model. Using the linear equation
generated from the mixed model, mean IFN-g concentrations
(ng/ml) were predicted to be, at baseline, 4, 12, 25 and 43 weeks
respectively: 6.4, 11.4, 12.6, 4.6 and 6.4 for placebo, compared
to 8.6, 8.8, 8.6, 5.6 and 4.7 respectively for the 400 IU daily
vitamin D treatment.TABLE 1 | Participant characteristics at baseline.
Placebo Vitamin D3(400 IU/d) All
n 31 28 59
Females, n (%) 19 (61.3) 21 (75.0) 40 (67.8)
Age (y) 50.0 (3.2) 43.6 (3.2) 47.0 (2.3)
Height (cm) 168 (1.8) 165.9 (2.1) 167.0 (1.3)
Weight (kg) 70.7 (2.2) 67.7 (2.6) 69.3 (1.7)
BMI (kg/m2) 25.0 (0.7) 24.6 (0.9) 24.8 (0.5)
Dietary vitamin D (µg/day) 2.6 (0.3) 3.3 (0.4) 3.0 (0.2)
Holiday abroad previous winter, n (%) 5 (16.1) 4 (14.3) 9 (15.3)
Cheek skin color (ITA) 41.8 (1.5) 43.2 (1.7) 42.4 (1.1)
Right Inner arm skin color (ITA) 54.4 (7.2) 51.9 (8.8) 53.5 (8.7)
Right outer arm skin color (ITA) 48.6 (1.1) 48.7 (1.8) 48.6 (1.0)
25(OH)D (nmol/L) 36.4 (3.2) 35.8 (3.0) 36.1 (2.2)
PTH (pmol/L) 5.3 (0.3) 4.8 (0.2) 5.1 (0.2)June 2021 | Volume 12 | ArtiNumber (%) for categorical variables (SEM). Mean (SEM) for continuous variables.
ITA, individual topology angle.cle 623087
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Our study demonstrates seasonal variation for markers of
vitamin D and all immune markers tested, with summer values
13%, 46%, 50%, 56% higher than in winter for %nTregs,
proliferation, IL-10 and IFN-g, respectively. However, daily
vitamin D3, at a physiologically relevant dose of 400IU for 43
weeks starting in March, did not affect %nTregs and other
immune markers in healthy volunteers. An additional findingFrontiers in Immunology | www.frontiersin.org 7was an interaction between season and vitamin D treatment,
whereby oral vitamin D attenuated the seasonal rise of IFN-g
observed for the placebo group in April, June, and January,
but not in September (when 25(OH)D is generally at its highest).
The tandem mass spec method used for the measurement of
vitamin D metabolites includes a de-lipidation procedure,
which results in greater recovery of 25(OH)D and allows the
measurement of other vitamin D metabolites such as 24,25(OH)
2D (included in this study) that circulate at lower concentrations
(24). Using over 2000 measurements of 25(OH)D done with and
without de-lipidation, the mean peak 25(OH)D values was
estimated to be 13 nmol/L higher than if the de-lipidation step
was not included (with less of a difference at lower values) (31).
Hence, after 25 weeks treatment with 400 IU daily vitamin D, the
25(OH)D peak would be 73 nmol/L without de-lipidation. In
addition, the lower starting 25(OH)D (late spring) results in a
greater increase in 25(OH)D than would be seen if the starting
25(OH)D were higher.
Evidence from five clinical trials comparing oral vitamin D3
with a control or placebo group on %nTregs is inconsistent.
Baris et al. (17) reported significantly higher %nTregs in
asthmatic children receiving pharmacotherapy after 12-months
of subcutaneous immunotherapy (SCIT) plus 650 IU/day
vitamin D compared with those receiving SCIT alone, and
Prietl et al. (16) observed 16% higher %nTregs with vitamin D
(140,000 IU/month) compared to placebo in a 12-week
wintertime study in healthy adults. In contrast, Gabbay et al.
(32) observed no differences in %nTregs between groups taking
2000 IU/day vitamin D3 or placebo in an 18-month study of
adults and children with new-onset Type 1 diabetes (T1D).
Similar %nTregs were reported between treatment groups for
adults with relapsing-remitting MS who underwent a 2-step
intervention with daily vitamin D3 (7000 IU for 4 weeks,
followed by 14000 IU for 44 weeks) (33). These results
corroborate our findings and those of Treiber et al. (18) in
children with new-onset T1D treated with ~3434 IU/day for 12
months in Austria. However, the latter study found significantly
higher Treg immunosuppressive capacity in the vitamin D
group, while Prietl et al. (16) found no change in Treg
immunosuppressive properties despite increased %nTregs (16).
Observational studies support a role for vitamin D on Treg
function in some patient groups (34), and correlations between
25(OH)D and Treg suppressive functionality have been observed
(18, 35), but these are subject to confounding.
Suggestions that vitamin D-mediated immunomodulatory
effects are dependent on high local concentrations of 1,25(OH)2D
have motivated the use of high doses of vitamin D (16). Our doses
comply with current recommendations (2), but may not have
been sufficient to drive 25(OH)D to the concentrations required
to increase Treg numbers. The safety of intermittent high dose
vitamin D has been questioned with an increased risk of falls and
fractures (36) and lower volumetric BMD (37). Increased vitamin
D resulted in concomitant increased plasma 24,25(OH)2D
indicating increased catabolism, suggesting other feedback





FIGURE 2 | Changes in circulating vitamin D metabolites and PTH (mean
and 95%CI error bars) over time; (A) 25(OH)D, (B) 1,25(OH)2D, (C) Ratio of
1,25(OH)2D to 24,25(OH)2D, (D) PTH.June 2021 | Volume 12 | Article 623087
Maboshe et al. Vitamin D3 and Immune MarkersDiscrepancies between studies testing oral vitamin D
supplementation on %nTregs may be related to heterogeneity
of study designs: the type of participants, the definition of Treg
populations, dose and dosing intervals of vitamin D (from 650/
day to 420,000 IU/month), and the trial duration (ranging from 3
to 18 months).
Importantly, there is a lack of information on the timing of
subjects’ and controls’ recruitment to appropriately conclude on
the results reported. The initial vitamin D status of the
population may be important. Our study had 30% people
< 25nmol/L 25(OH)D, which is typical of this Northerly
latitude population in early spring, compared to 32% of people
< 50nmol/L 25(OH)D for the Prietl study (16).
The physiological consequences of the attenuation of the
seasonal rise of IFN-g by oral vitamin D observed for the
placebo group in April, June, and January are unclear. We
used production of the cytokine IFN-g by T cells stimulated in
vitro as an indicator of the strength of effector responses
associated with inflammation, but the ability to mount
inflammation or immunity to viral infection in vivo will not
necessarily be directly correlated with these results. The study
participants were all healthy, so any conclusions about
susceptibility to disease can only be suggestive without in vivo
challenge experiments. The increase in IFN-g observed in the
placebo group might be explained by 1,25(OH)2D’s direct
interference with the IFN-g promoter activity (38) or its Th2-
promoting action (39), which reciprocally antagonizes IFN-g-
driven Th1 responses. Mosayebi et al. (40) reported no effectsFrontiers in Immunology | www.frontiersin.org 8of ~11,000 IU/day intramuscular vitamin D on IFN-g after 6
months. Comparing our results with trials involving patients
(41), healthy subjects (42, 43) or overweight/healthy obese
subjects (44) is limited by the route of entry and dosage of
vitamin D and differences in cytokine assessment, which were
carried out using serum. None of the studies considered the
impact of seasonal variation on IFN-g and other cytokines.
Seasonal variations in Treg-specific and other immune markers
have been reported, but are often attributed to the seasonality of
vitamin D synthesis (19, 45). We observed seasonal variations in
25(OH)D concentrations in the placebo group consistent with
living at 57°N (28, 30, 46). Our study design allows us to suggest
that the seasonal changes in immune markers may be
independent of cutaneous vitamin D synthesis. We noted
subtle differences in the seasonal variations: %nTreg followed
the same pattern of 25(OH)D, which peaked in June &
September; T-effector proliferation responses were highest in
June, decreasing in September, whereas IL-10 and IFN-g
productions were higher in April and June than September
and January. These seasonal variations confirm previous
reports in non-intervention studies at 52°N in the Netherlands
(19, 45), gene expression studies in UK and Netherlands cohorts
(20) (47) and a randomized control trial with 2000 IU/d vitamin
D in healthy participants (43).
Seasonal patterns of human immune activity may reflect
responses to environmentally driven factors. Ter Horst et al.
(47) reported annual seasonality of immune and cytokine
production, which paralleled peaks in summer temperatureA
B
FIGURE 3 | Changes in immune cell responses over time. (A) Circulating proportion of Tregs; (B) T-effector cell proliferation.June 2021 | Volume 12 | Article 623087
Maboshe et al. Vitamin D3 and Immune Markersand atmospheric NH3 and O2 levels, wintertime humidity, SO2,
NO, NO2, and CO concentrations, and different species of pollen
at different times of the year (47). Melatonin, which has
immunomodulatory properties (48–50), may be key to
understanding photoperiod-driven changes in host immune
activity. However, evidence from seasonally controlled clinical
trials is needed.
The main strengths of this study were good compliance, low
dropout rates, and strict inclusion criteria to control for
confounders known to affect vitamin D status and
immune function. All study visits started in March, before the
appearance of UVB (46). Our placebo arm was contemporaneous
to the supplementation arm, and all study visits were conducted
within 1 month to properly account for sunlight exposure and
seasonal effects over the 10-month study. To our knowledge, no
previous vitamin D supplementation study has adequately
accounted for the seasonal variability in the immune system
activity. The dose used is the daily dose of vitamin D
recommended by the UK government for adults in the
population. However, we did not directly assess TregFrontiers in Immunology | www.frontiersin.org 9immunoregulatory activity, and we measured only two cytokines
to explore the effects of vitamin D supplementation on ex-vivo T
cell responses. It would be of interest in future studies to also
enumerate other regulatory populations, such as Br1, Br3 and Breg
cells, but here we chose to focus on cells with a nTreg phenotype,
since these comprise the most widely studied, most numerous, and
arguably most important, regulatory population in health and in
many immune-mediated diseases. In addition to the Treg
considered in this study, there are other regulatory populations,
including T-cell subsets that arise in the periphery and secrete
inhibitory cytokines, such as Tr1 (IL-10) and Th3 (TGF-b). Il-10
secreting T cells in particular have been associated with protection
or recovery from allergies and autoimmune disease and may in
vivo include both tTreg and Tr1 subsets. The production of the
effector Th17 cytokine IL-17 would also have been of interest.
Given the constraints of experimental design, we used IL-10
produced by PBMC incubated with T cell stimuli as an
indicator of the responsiveness of such regulatory cells and IFN-
g production by stimulated T cells as an indicator of effector
function, as it would have been challenging to enumerate T cellsA
B
FIGURE 4 | Box plots showing changes in activated cell-produced cytokine concentrations over time (A) IL-10 (B) IFN-g. The box plots follow the conventional
format with the bottom and top of the box corresponding to the 25th and 75th centile, respectively; the internal bar being the median; the whiskers, 1.5X the box
height, with the outlying dots denoting the outliers i.e. cases that do not fall within the whiskers.June 2021 | Volume 12 | Article 623087
Maboshe et al. Vitamin D3 and Immune Markerssecreting inhibitory cytokines including IL-10 and TGF-b in
addition to the measurements already carried out. Furthermore,
other markers and signaling pathways could have been of interest
in studying different types of regulatory cells and their activity
such as STAT4, STAT6, T-bet and others. However, given the
constraints of sample size and expense, we chose outputs that gave
the clearest indications of regulation (enumeration of the classic
nTreg subset in blood and production of the key inhibitory
cytokine IL-10 by stimulated T cells). Lastly, the generalization
of our results is limited by the lack of ethnic diversity in our
study population.
In conclusion, we observed seasonality of both circulating
vitamin D markers and the immune responses that we assessed.
However, additional vitamin D as oral supplementation did not
affect the natural seasonal variation in %nTregs, nor ex-vivo T-
effector cell proliferation and IL-10 response to stimulation. The
novel finding that vitamin D attenuated T cell IFN-g production
suggests that vitamin D may partly modulate the immune
response in healthy adults.Frontiers in Immunology | www.frontiersin.org 10DATA AVAILABILITY STATEMENT
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